| Item | Correct answers, n (%) | Knowledge score (%) | ||||
| Question 8. What data are included in the monitoring of anti-epileptic treatment? |
| 43.8 | ||||
|
| Q8.1. Clinical monitoring data |
|
| |||
|
|
| Presence/persistence of seizures | 118 (86.1) |
| ||
|
|
| Psychomotor development and learning of the child | 102 (74.4) |
| ||
|
|
| Adverse events related to the treatment of epilepsy | 102 (74.4) |
| ||
|
|
| Therapeutic compliance | 68 (49.6) |
| ||
|
|
| Cognitive disorders | 67 (48.9) |
| ||
|
|
| Impact of epilepsy on the patient’s daily life | 67 (48.9) |
| ||
|
|
| Attention deficit disorders | 52 (38) |
| ||
|
|
| Depression | 51 (37.2) |
| ||
|
|
| Suicide risk | 41 (29.9) |
| ||
|
|
| Anxiety syndrome | 31 (22.6) |
| ||
|
|
| Nutritional status and measurements (weight; height) | 29 (21.2) |
| ||
|
| Q8.2. Paraclinical monitoring data |
|
| |||
|
|
| EEG | 93 (67.9) |
| ||
|
|
| Serum transaminase activities | 43 (31.4) |
| ||
|
|
| Creatinemia | 41 (29.9) |
| ||
|
|
| Blood determination of drugs | 26 (19) |
| ||
|
|
| Blood count | 21 (15.3) |
| ||
| Question 9. What are the times for monitoring the effectiveness of anti-epileptic treatment? |
| 24.1 | ||||
|
|
| At the third month after starting treatment | 44 (32.1) |
| ||
|
|
| Every six months after starting treatment | 22 (16.1) |
| ||